Cargando…
Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland
INTRODUCTION: Omalizumab has been successfully used as a supplementary therapy to improve asthma control in children aged ≥ 6 years with moderate or severe persistent allergic asthma. AIM: To evaluate effectiveness ofomalizumab in children and adolescents with uncontrolled allergic asthma. MATERIAL...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330849/ https://www.ncbi.nlm.nih.gov/pubmed/34377123 http://dx.doi.org/10.5114/ada.2021.107929 |
_version_ | 1783732805487820800 |
---|---|
author | Sztafińska, Anna Gwardys, Mikołaj Podlecka, Daniela Mospinek, Ewa Stelmach, Iwona |
author_facet | Sztafińska, Anna Gwardys, Mikołaj Podlecka, Daniela Mospinek, Ewa Stelmach, Iwona |
author_sort | Sztafińska, Anna |
collection | PubMed |
description | INTRODUCTION: Omalizumab has been successfully used as a supplementary therapy to improve asthma control in children aged ≥ 6 years with moderate or severe persistent allergic asthma. AIM: To evaluate effectiveness ofomalizumab in children and adolescents with uncontrolled allergic asthma. MATERIAL AND METHODS: Seventeen children and adolescents aged 8–16, treated with omalizumab from 2011 until now, were enrolled into the retrospective, open, uncontrolled, observational study. The effectiveness of therapy, asthma control, quality of life, exacerbation rate, corticosteroid use, were assessed after 16, 52 and 104 weeks of treatment and after omalizumab cessation. RESULTS: The response to treatment was assessed as excellent (9 patients) and good (6 patients), according to global evaluation of treatment effectiveness (GETE). A statistically significant decrease in use of oral corticosteroids (OCS) and leukotriene receptor antagonists (LTRAs) was observed. The doses of inhaled corticosteroids (ICS) decreased significantly (the mean dose of ICS converted to a dose of budesonide before treatment was 1503.53 μg/day versus 903.53 μg after discontinuation). The mean asthma control questionnaire (ACQ) value decreased from 2.10 to 0.84 points and the mean mini asthma quality of life questionnaire (miniAQLQ) outcome increased from 4.37 to 6.1 points. The mean number of exacerbations decreased from 5.59 to 0.53 per year. CONCLUSIONS: Our results are supportive of the existing evidence that omalizumab therapy improves asthma control, reduces OCS and ICS use, decreases exacerbations in children and adolescents with severe/moderate uncontrolled allergic asthma. |
format | Online Article Text |
id | pubmed-8330849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-83308492021-08-09 Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland Sztafińska, Anna Gwardys, Mikołaj Podlecka, Daniela Mospinek, Ewa Stelmach, Iwona Postepy Dermatol Alergol Original Paper INTRODUCTION: Omalizumab has been successfully used as a supplementary therapy to improve asthma control in children aged ≥ 6 years with moderate or severe persistent allergic asthma. AIM: To evaluate effectiveness ofomalizumab in children and adolescents with uncontrolled allergic asthma. MATERIAL AND METHODS: Seventeen children and adolescents aged 8–16, treated with omalizumab from 2011 until now, were enrolled into the retrospective, open, uncontrolled, observational study. The effectiveness of therapy, asthma control, quality of life, exacerbation rate, corticosteroid use, were assessed after 16, 52 and 104 weeks of treatment and after omalizumab cessation. RESULTS: The response to treatment was assessed as excellent (9 patients) and good (6 patients), according to global evaluation of treatment effectiveness (GETE). A statistically significant decrease in use of oral corticosteroids (OCS) and leukotriene receptor antagonists (LTRAs) was observed. The doses of inhaled corticosteroids (ICS) decreased significantly (the mean dose of ICS converted to a dose of budesonide before treatment was 1503.53 μg/day versus 903.53 μg after discontinuation). The mean asthma control questionnaire (ACQ) value decreased from 2.10 to 0.84 points and the mean mini asthma quality of life questionnaire (miniAQLQ) outcome increased from 4.37 to 6.1 points. The mean number of exacerbations decreased from 5.59 to 0.53 per year. CONCLUSIONS: Our results are supportive of the existing evidence that omalizumab therapy improves asthma control, reduces OCS and ICS use, decreases exacerbations in children and adolescents with severe/moderate uncontrolled allergic asthma. Termedia Publishing House 2021-07-26 2021-06 /pmc/articles/PMC8330849/ /pubmed/34377123 http://dx.doi.org/10.5114/ada.2021.107929 Text en Copyright: © 2021 Termedia Sp. z o. o. https://creativecommons.org/licenses/by-nc-nd/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Paper Sztafińska, Anna Gwardys, Mikołaj Podlecka, Daniela Mospinek, Ewa Stelmach, Iwona Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland |
title | Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland |
title_full | Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland |
title_fullStr | Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland |
title_full_unstemmed | Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland |
title_short | Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland |
title_sort | effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from poland |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330849/ https://www.ncbi.nlm.nih.gov/pubmed/34377123 http://dx.doi.org/10.5114/ada.2021.107929 |
work_keys_str_mv | AT sztafinskaanna effectivenessofomalizumabinchildrenandadolescentswithuncontrolledallergicasthmaacaseseriesfrompoland AT gwardysmikołaj effectivenessofomalizumabinchildrenandadolescentswithuncontrolledallergicasthmaacaseseriesfrompoland AT podleckadaniela effectivenessofomalizumabinchildrenandadolescentswithuncontrolledallergicasthmaacaseseriesfrompoland AT mospinekewa effectivenessofomalizumabinchildrenandadolescentswithuncontrolledallergicasthmaacaseseriesfrompoland AT stelmachiwona effectivenessofomalizumabinchildrenandadolescentswithuncontrolledallergicasthmaacaseseriesfrompoland |